Q&A: Mark McClellan Discusses Gottlieb, Cures And More
Executive Summary
Former FDA Commissioner Mark McClellan talked with Medtech Insight about FDA Commissioner-nominee Scott Gottlieb, who he has worked closely with in the past at FDA and CMS. He also discussed 21st Century Cures Implementation, President Trump's budget blueprint and more.
You may also be interested in...
Trump Budget: FDA-Regulated Firms Should Pay 'Their Share' In User Fees
President Trump's initial budget plan for US FDA would, it appears, make industry-paid user fees a much larger proportion of the agency's budget, but details are lacking. As is, the plan could complicate agreements that came out of FDA-industry user-fee negotiations last summer, but observers say this is just the first step in a process and Congress will ultimately decide. Trump would also shave 22% from the National Institutes of Health.
FDA Confirmation Watch: Gottlieb Likely To Face Questions About Approval Standards, Ties To Industry
Top HELP Committee Democrat Patty Murray tweeted concerns about Gottlieb's positions on the "gold standard" of FDA approval; Pubic Citizen's Michael Carome ultimately thinks Gottlieb will be approved.
Gottlieb At FDA: Industry Will Look For User-Fee Deal Support, Restrained Regulations
After months of waiting on whether President Trump would pick a conventional FDA commissioner candidate or go off the beaten path, the White House appears to be taking the former approach. Trump is expected to nominate Scott Gottlieb, a George W. Bush administration FDA alum, physician and long-time conservative voice on health policy. Gottlieb will favor reduced regulatory burdens, and industry hopes he will help push forward a device user-fee reauthorization agreement.